LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned ...
The current trend of using two cannulas to place most newborns in respiratory failure on life-sustaining ECMO, one in the right internal jugular vein and a second in the right common carotid artery, ...
San Antonio, Texas – June 3, 2024 – Recognizing an unusual prevalence of bloodstream infections (BSI) that threatened extremely ill patients receiving Extracorporeal Membrane Oxygenation, or ECMO, ...
Use of left atrial venoarterial cannulation during extracorporeal membrane oxygenation—a technique known as LAVA ECMO—appears to be a safe and feasible means of support for patients with cardiogenic ...
A certain approach to extracorporeal membrane oxygenation (ECMO) in COVID-19 patients showed a high success rate at two centers in Chicago, researchers reported. Of 40 recipients, 29 (73%) were ...
(UPDATED) In the race to save lives, physicians have turned to extracorporeal membrane oxygenation (ECMO) and, more rarely, other forms of mechanical circulatory support (MCS) to overcome lung and ...
Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results